$VCNX
Vaccinex Inc

2018 Q4 Form 10-Q Financial Statement

#000156459018029125 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $190.0K $198.0K $0.00
YoY Change 111.11%
Cost Of Revenue $300.0K $246.0K $0.00
YoY Change 87.5%
Gross Profit -$110.0K -$48.00K $0.00
YoY Change 57.14%
Gross Profit Margin -57.89% -24.24%
Selling, General & Admin $1.380M $1.090M $1.040M
YoY Change 25.45% 4.81%
% of Gross Profit
Research & Development $7.070M $5.314M $4.290M
YoY Change 40.56% 23.87%
% of Gross Profit
Depreciation & Amortization $50.00K $54.00K $50.00K
YoY Change -16.67% 8.0%
% of Gross Profit
Operating Expenses $8.460M $5.314M $5.330M
YoY Change 38.01% -0.3%
Operating Profit -$8.570M -$6.454M -$5.330M
YoY Change 38.23% 21.09%
Interest Expense $0.00 $44.00K -$200.0K
YoY Change -100.0% -122.0%
% of Operating Profit
Other Income/Expense, Net $110.0K $70.00K $0.00
YoY Change -650.0%
Pretax Income -$8.450M -$6.600M -$5.540M
YoY Change 221.29% 19.13%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.450M -$6.600M -$5.540M
YoY Change 226.25% 19.13%
Net Earnings / Revenue -4447.37% -3333.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$736.1K -$575.4K -$483.0K
COMMON SHARES
Basic Shares Outstanding 11.48M 11.48M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.72M $27.38M
YoY Change
Cash & Equivalents $5.618M $11.26M $429.0K
Short-Term Investments $14.11M $16.12M
Other Short-Term Assets $1.060M $1.560M
YoY Change
Inventory
Prepaid Expenses
Receivables $639.0K $403.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $21.42M $29.34M
YoY Change 330.72%
LONG-TERM ASSETS
Property, Plant & Equipment $604.0K $544.0K
YoY Change 0.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $604.0K $544.0K
YoY Change 0.5%
TOTAL ASSETS
Total Short-Term Assets $21.42M $29.34M
Total Long-Term Assets $604.0K $544.0K
Total Assets $22.03M $29.88M
YoY Change 295.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.322M $2.276M
YoY Change 21.57%
Accrued Expenses $4.364M $3.818M
YoY Change 122.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.686M $6.136M
YoY Change 60.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.686M $6.136M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.686M $30.10M
YoY Change -9.0%
SHAREHOLDERS EQUITY
Retained Earnings -$216.8M
YoY Change 15.76%
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $11.00K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$8.621M -$220.0K
YoY Change
Total Liabilities & Shareholders Equity $22.03M $29.88M
YoY Change 295.12%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$8.450M -$6.600M -$5.540M
YoY Change 226.25% 19.13%
Depreciation, Depletion And Amortization $50.00K $54.00K $50.00K
YoY Change -16.67% 8.0%
Cash From Operating Activities -$7.560M -$7.220M -$4.730M
YoY Change 20.96% 52.64%
INVESTING ACTIVITIES
Capital Expenditures -$170.0K -$10.00K -$10.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $2.080M -$16.09M $0.00
YoY Change
Cash From Investing Activities $1.920M -$16.10M -$10.00K
YoY Change 160900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 33.28M 4.000M
YoY Change -100.0% 732.0%
NET CHANGE
Cash From Operating Activities -7.560M -7.220M -4.730M
Cash From Investing Activities 1.920M -16.10M -10.00K
Cash From Financing Activities 0.000 33.28M 4.000M
Net Change In Cash -5.640M 9.960M -740.0K
YoY Change -250.4% -1445.95%
FREE CASH FLOW
Cash From Operating Activities -$7.560M -$7.220M -$4.730M
Capital Expenditures -$170.0K -$10.00K -$10.00K
Free Cash Flow -$7.390M -$7.210M -$4.720M
YoY Change 18.24% 52.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
311000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11475749
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11258000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4180000
CY2018Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16121000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
117000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
677000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
4974000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
601000
CY2017Q4 us-gaap Assets
Assets
5575000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1910000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1957000
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
2813000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
403000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1555000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
29337000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
544000
CY2018Q3 us-gaap Assets
Assets
29881000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2276000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3818000
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
42000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
298000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6136000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4165000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
369000
CY2017Q4 us-gaap Liabilities
Liabilities
7347000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
1000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
111718000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2379000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16132000
us-gaap Profit Loss
ProfitLoss
-16132000
us-gaap Net Income Loss
NetIncomeLoss
-16132000
CY2018Q3 ck0001205922 Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-6599000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
ck0001205922 Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
7684000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1661000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
429000
us-gaap Interest Paid Net
InterestPaidNet
275000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7078715
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-107065000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
249000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
286000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
878000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
456000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
323000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
60000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1861000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-169000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-256000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
69000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17719000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16092000
ck0001205922 Purchase Of Property And Equipment Included In Accounts Payable
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable
52000
ck0001205922 Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
111718000
us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
12000000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
ck0001205922 Temporary Equity Stock Issued Issuance Costs
TemporaryEquityStockIssuedIssuanceCosts
18000
us-gaap Depreciation
Depreciation
166000
us-gaap Depreciation
Depreciation
152000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
308000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
886000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
29000
us-gaap Share Based Compensation
ShareBasedCompensation
131000
us-gaap Share Based Compensation
ShareBasedCompensation
249000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
5976000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
37125000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2675000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
5500000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
12000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40955000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13973000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7078000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1232000
CY2017Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
324000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates. </p></div>
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
357014
us-gaap Interest Expense Debt
InterestExpenseDebt
308000
us-gaap Interest Expense Debt
InterestExpenseDebt
886000
CY2016Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
31000000000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Other Risks and Uncertainties </p> <p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Cash equivalents are deposited in interest-bearing money market accounts and short-term investments consist of highly liquid U.S. government treasury bills and notes. The Company deposits its cash with multiple financial institutions and cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company&#8217;s product candidates and adversely impact its results of operations. </p></div>
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.60
ck0001205922 Royalty Payments Percent Of Net Sales
RoyaltyPaymentsPercentOfNetSales
0.01
CY2018Q3 ck0001205922 Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
14000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
350000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
42000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
42000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
126000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
420956
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
28000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
700
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44570
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
126000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
287000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
227000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
192000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
324000
CY2018Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
16121000
CY2018Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
16121000
CY2017Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
369000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
-369000
CY2018Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
17000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6811000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6267000
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
152000
CY2018Q3 ck0001205922 Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
3260000
CY2017Q4 ck0001205922 Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
891000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
189000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
131000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
249000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2401000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.10
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.10
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.71
CY2018Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
9.49
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5021000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4598000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4146000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
176000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13000
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
471000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
216000
ck0001205922 Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumContractualTerm
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
809000
ck0001205922 Number Of Business Activity
NumberOfBusinessActivity
1
ck0001205922 Number Of Segment Managers For Operations Or Operating Results
NumberOfSegmentManagersForOperationsOrOperatingResults
0
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-08-17

Files In Submission

Name View Source Status
0001564590-18-029125-index-headers.html Edgar Link pending
0001564590-18-029125-index.html Edgar Link pending
0001564590-18-029125.txt Edgar Link pending
0001564590-18-029125-xbrl.zip Edgar Link pending
ck0001205922-10q_20180930.htm Edgar Link pending
ck0001205922-20180930.xml Edgar Link completed
ck0001205922-20180930.xsd Edgar Link pending
ck0001205922-20180930_cal.xml Edgar Link unprocessable
ck0001205922-20180930_def.xml Edgar Link unprocessable
ck0001205922-20180930_lab.xml Edgar Link unprocessable
ck0001205922-20180930_pre.xml Edgar Link unprocessable
ck0001205922-ex311_7.htm Edgar Link pending
ck0001205922-ex312_6.htm Edgar Link pending
ck0001205922-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending